Humana (NYSE:HUM) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Humana (NYSE:HUM) in a research note published on Thursday, Benzinga reports. The brokerage currently has a $597.00 price objective on the insurance provider’s stock.

HUM has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft upped their target price on shares of Humana from $468.00 to $628.00 and gave the stock a buy rating in a report on Monday, August 7th. Stephens boosted their target price on Humana from $555.00 to $560.00 and gave the stock an overweight rating in a research report on Thursday, August 3rd. JPMorgan Chase & Co. downgraded Humana from an overweight rating to a neutral rating and dropped their price target for the company from $576.00 to $540.00 in a research report on Friday, July 7th. Royal Bank of Canada decreased their price objective on shares of Humana from $637.00 to $594.00 and set an outperform rating on the stock in a research report on Thursday, August 3rd. Finally, Morgan Stanley cut their price target on shares of Humana from $637.00 to $624.00 and set an overweight rating for the company in a research note on Wednesday, August 30th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average target price of $594.53.

Humana Stock Down 0.2 %

Shares of NYSE HUM opened at $470.77 on Thursday. The business’s fifty day moving average price is $468.27 and its 200-day moving average price is $486.74. The stock has a market capitalization of $58.33 billion, a PE ratio of 17.57, a P/E/G ratio of 1.22 and a beta of 0.66. Humana has a one year low of $423.29 and a one year high of $571.30. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.37 and a quick ratio of 1.37.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $8.94 EPS for the quarter, topping analysts’ consensus estimates of $8.88 by $0.06. The firm had revenue of $26.75 billion during the quarter, compared to analyst estimates of $25.83 billion. Humana had a return on equity of 20.70% and a net margin of 3.42%. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the company earned $8.67 earnings per share. On average, equities research analysts anticipate that Humana will post 28.25 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be given a $0.885 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.75%. Humana’s dividend payout ratio is currently 13.21%.

Institutional Trading of Humana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Portside Wealth Group LLC purchased a new position in shares of Humana in the 2nd quarter valued at approximately $786,000. Alberta Investment Management Corp lifted its position in Humana by 66.3% during the 2nd quarter. Alberta Investment Management Corp now owns 20,399 shares of the insurance provider’s stock valued at $9,121,000 after acquiring an additional 8,131 shares during the period. Virginia Retirement Systems ET AL bought a new stake in Humana during the second quarter worth about $14,452,000. Comerica Bank purchased a new stake in Humana in the second quarter worth about $99,470,000. Finally, Osaic Holdings Inc. lifted its holdings in shares of Humana by 35.6% during the second quarter. Osaic Holdings Inc. now owns 24,660 shares of the insurance provider’s stock valued at $11,008,000 after purchasing an additional 6,469 shares during the last quarter. Hedge funds and other institutional investors own 91.86% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.